Basic Stats
| LEI | 254900QL5GLNKGR8YH71 |
| CIK | 1745999 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Beam Therapeutics Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| August 5, 2025 |
Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Explor |
|
| August 5, 2025 |
Amended and Restated Non-Employee Director Compensation Policy, dated June 2, 2025. Exhibit 10.1 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of June 2, 2025) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the following |
|
| July 3, 2025 |
FORM 8-K Item 3.02 Unregistered Sales of Equity Securities. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 6, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 04, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 6, 2025 |
Exhibit 99.1 Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Accepted for Presentation at the European Hematology Association 2025 Congress in June |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 10, 2025 |
Joint bookrunning managers J.P. Morgan Jefferies Cantor Citigroup Wells Fargo Securities As Filed Pursuant to Rule 424(b)(5) Registration No. 333-277427 Prospectus supplement (To prospectus dated February 28, 2024) 16,151,686 shares of common stock Pre-funded warrants to purchase 1,404,988 shares of common stock This is an offering of 16,151,686 shares of the common stock of Beam Therapeutics Inc. and, in lieu of common stock for certain investors that so choose, pre-funded warrants t |
|
| March 10, 2025 |
Beam Therapeutics Announces Pricing of Underwritten Offering Exhibit 99.1 Beam Therapeutics Announces Pricing of Underwritten Offering Cambridge, Mass., March 10, 2025 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of an underwritten offering of 16,151,686 shares of its common stock at an offering price of $28.48 per share, and, in lieu of common stock |
|
| March 10, 2025 |
Exhibit 4.1 BEAM THERAPEUTICS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: [], 2025 Beam Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its permitted registered assign |
|
| March 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics Inc. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 10, 2025 |
Joint bookrunning managers J.P. Morgan Jefferies Cantor Citigroup Wells Fargo Securities Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-277427 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement filed with the Securities and Exchange Commission relating to these securities is effective. This preliminary prospectus supplement is not an offer to sell these securities and we are not solicitin |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 10, 2025 |
BEAM THERAPEUTICS INC. Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock FWP 1 d926256dfwp.htm FWP Issuer Free Writing Prospectus dated March 10, 2025 Filed Pursuant to Rule 433 Registration No. 333-277427 BEAM THERAPEUTICS INC. Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock This free writing prospectus relates only to the offering by Beam Therapeutics Inc. of shares of common stock and, in lieu of shares of common stock for certain inves |
|
| March 10, 2025 |
Exhibit 99.1 Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT |
|
| March 10, 2025 |
Exhibit 1.1 Beam Therapeutics Inc. 16,151,686 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,404,988 Shares of Common Stock Underwriting Agreement March 10, 2025 J.P. Morgan Securities LLC Jefferies LLC Cantor Fitzgerald & Co. Citigroup Global Markets Inc. Wells Fargo Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities |
|
| February 25, 2025 |
Exhibit 10.42 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. AMENDMENT NO. 4 TO LICENSE AGREEMENT This Amendment (“Amendment No. 4”), effective as of December 11, 2024 (“Amendment No. 4 Effective Date”), is entered into by and between Be |
|
| February 25, 2025 |
Exhibit 19.1 Beam Therapeutics Inc. Insider Trading Policy (as amended and restated as of December 5, 2024) 1. Purpose. This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of, and handling confidential information about, Beam Therapeutics Inc. (the “Company”) and Applicable Other Companies (as defined below). The Company’s Board of Directo |
|
| February 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti |
|
| February 25, 2025 |
Letter Agreement between Beam Therapeutics Inc. and Sravan K. Emany, dated December 2, 2024 Exhibit 10.18 November 25, 2024 Mr. Sravan K. Emany 811 Cedar Terrace Westfield N.J. 07090 Re: Offer of Employment Dear Sravan, Beam Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Start Date. Provided that you satisfy the conditions described at the end of this letter agreement (this “Agreement”), your first day of employment with the Company will |
|
| February 25, 2025 |
As filed with the Securities and Exchange Commission on February 25, 2025 As filed with the Securities and Exchange Commission on February 25, 2025 Registration No. |
|
| February 25, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par |
|
| February 25, 2025 |
Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 30 Patients and Updated Data Expected by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing Exp |
|
| February 14, 2025 |
EX-1 2 exh118926.htm AGREEMENT Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Beam Therapeutics, Inc. This Agreement may be executed in any number of counte |
|
| February 5, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EX-1 2 jas.htm JOINT ACQUISITION STATEMENT EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| January 13, 2025 |
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency Expected in First Half 2025 Dosing |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 13, 2025 |
PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 PRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| December 9, 2024 |
Exhibit 99.1 Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety Profile Consistent with Busulfan |
|
| December 9, 2024 |
Exhibit 99.2 Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cel |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 6, 2024 |
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer Exhibit 99.1 Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer Cambridge, Mass., December 6, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a br |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 4, 2024 |
Exhibit 99.1 Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader Cambridge, Mass., December 4, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at M |
|
| November 7, 2024 |
BEAM / Beam Therapeutics Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 beam13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| November 5, 2024 |
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting Initial Results from BEACON Phase 1/2 Clinical Trial Demonstrate Potential for Differentiation of Base Editing and BEAM-101 Preclinical ESCAPE Data Establish Proof-of-concept for Non-genotoxic, Antibody-based Conditioning and Engraftment in Non-human Primates Clinical Data from Phase 1/2 BEAM-201 Trial Demonstrate Therapeutic Potential of First Quadruplex-edited Allogeneic CAR-T Cell Therapy Beam to Host Investor Event on Dec. |
|
| November 5, 2024 |
Q3 Financial Results & ASH Abstracts Investor Webcast November 5, 2024 Q3 Financial Results & ASH Abstracts Investor Webcast November 5, 2024 Beam conference call participants Beam’s Sickle Cell Disease Strategy Q3 Business Update Introduction ASH Abstract: ESCAPE Preclinical Data ASH Abstracts: BEAM-101 Clinical Data Mr. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T |
|
| November 5, 2024 |
Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting 35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease First Cohort |
|
| November 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 5, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| October 17, 2024 |
BEAM / Beam Therapeutics Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 BeamTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BEAM THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 07373V105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| August 6, 2024 |
Exhibit 10.3 Third Amendment to License Agreement This Third Amendment (“Amendment”), effective as of May 31, 2024 (“Amendment Effective Date”), is entered into by and between Beam Therapeutics Inc., as a successor in interest to Blink Therapeutics Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 238 Main Street, 9th Floor, Cambridge, Massachusett |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| August 6, 2024 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| July 15, 2024 |
Beam Therapeutics Announces Transition of Chief Financial Officer Exhibit 99.1 Beam Therapeutics Announces Transition of Chief Financial Officer Cambridge, Mass., July 15, 2024 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chair |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 7, 2024 |
Exhibit 10.2 [-] RE: Addendum to Executive Letter Agreement Dear [-], This letter serves as an addendum to your Executive Letter Agreement, dated [-]. See Appendix A for details around the revisions to your severance provisions. All other terms and conditions of your original letter of offer remain the same. Sincerely, [-] Beam Therapeutics, Inc. Acceptance: I understand and accept the conditions |
|
| May 7, 2024 |
Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy Exhibit 10.1 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of April 1, 2024) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the followin |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| May 7, 2024 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Clinical Trial Authorisation (CTA) Application Cleared for the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Study to Initiate in First Half of 2024 BEAM |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| February 28, 2024 |
EX-4.3 Exhibit 4.3 BEAM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) |
|
| February 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Beam Therapeutics Inc. |
|
| February 28, 2024 |
EX-4.5 Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| February 28, 2024 |
Form of Subordinated Indenture EX-4.4 Exhibit 4.4 BEAM THERAPEUTICS INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.086.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.014.04 312(b) 4.04 (c) 312(c) 4.04 (c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 |
|
| February 28, 2024 |
EX-1.2 Exhibit 1.2 BEAM THERAPEUTICS INC. SALES AGREEMENT April 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Beam Therapeutics Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Com |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 28, 2024 |
EX-4.6 Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N |
|
| February 27, 2024 |
Exhibit 10.29 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of January 22, 2024) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the foll |
|
| February 27, 2024 |
Exhibit 97.1 BEAM THERAPEUTICS INC. Clawback Policy This Clawback Policy (this “Policy”), adopted by Beam Therapeutics Inc. (the “Company”), relates to the Company’s right to recover compensation previously paid to specified employees in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), wh |
|
| February 27, 2024 |
Exhibit 10.40 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this “Second Amendment”) is made as of March 31, 2023, by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11, 2020, as amended b |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 27, 2024 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per sha |
|
| February 27, 2024 |
Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation for BEAM-302 in Alpha-1 Antitrypsin Deficiency on Track for First Half o |
|
| February 27, 2024 |
As filed with the Securities and Exchange Commission on February 27, 2024 As filed with the Securities and Exchange Commission on February 27, 2024 Registration No. |
|
| February 27, 2024 |
Exhibit 10.39 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “First Amendment”) is made as of June 23, 2022, by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11, 2020 (the “Lease”), wh |
|
| February 27, 2024 |
Exhibit 10.41 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this “Third Amendment”) is made as of January 1st, 2024 (“Effective Date”), by and between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 11, |
|
| February 14, 2024 |
SC 13G/A 1 arch-sch13g18793.htm ARCH VENTURE FUND IX, L.P. - BEAM THERAPEUTICS - SCH 13G/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Beam Therapeutics, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2023 (Date |
|
| February 13, 2024 |
BEAM / Beam Therapeutics Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Beam Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 12, 2024 |
BEAM / Beam Therapeutics Inc. / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 beam13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| February 6, 2024 |
BEAM / Beam Therapeutics Inc. / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Secur |
|
| January 29, 2024 |
BEAM / Beam Therapeutics Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d10sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Beam Therapeutics Inc. (Name of Issuer) Common stock (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| January 8, 2024 |
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024 Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 08, 2024 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 8, 2024 |
PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| December 14, 2023 |
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors EX-99.1 Exhibit 99.1 Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors CAMBRIDGE, Mass., Dec. 14, 2023 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company’s board of directors. “Christi is an inspiring leader who knows firsthand |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T |
|
| November 8, 2023 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Lilly Acquires Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Cardiovascular Programs for up to $600 Million in Combined Upfront Payment, E |
|
| October 31, 2023 |
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026 CAMBRIDGE, Mass. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 19, 2023 |
EX-99.1 PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs, |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission |
|
| October 19, 2023 |
EX-99.2 Exhibit 99.2 Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company t |
|
| September 22, 2023 |
BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 20, 2023 |
Rule 83 Confidential Treatment Request by Beam Therapeutics Inc. Request #1 CONFIDENTIAL TREATMENT REQUEST UNDER RULE 83 The entity requesting confidential treatment is: Beam Therapeutics Inc. |
|
| August 9, 2023 |
August 9, 2023 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Mary Mast and Ms. Angela Connell Re: Beam Therapeutics Inc. Form 10-K for the Year Ended December 31, 2022 Filed February 28, 2023 File No. 001-39208 Dear Ms. Mast and Ms. Connell: Beam Therapeutics Inc. (“Beam”) prov |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| August 8, 2023 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of BEAM-201 in T-ALL/T-LL and Expected to be Dosed in The Third Quarter of 2023 Company to Accelerate Develo |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2023 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| May 10, 2023 |
Letter Agreement between Beam Therapeutics Inc. and Christine Bellon, dated January 24, 2020 January 24, 2020 Dear Christine, This letter agreement (this "Agreement") confirms the terms and conditions of your employment with Beam Therapeutics Inc. |
|
| May 10, 2023 |
Letter Agreement between Beam Therapeutics Inc. and Amy Simon, dated January 29, 2021 January 29, 2021 Amy R. Simon, M.D. 18 Hammond Street Chestnut Hill, MA 02467 Dear Amy, This letter agreement (this “Agreement”) confirms the terms and conditions of your employment with Beam Therapeutics Inc. (the “Company”), effective as of March 22, 2021 (the “Effective Date”). 1. Position. Your position with the Company will be Chief Medical Officer. You agree to perform the duties of your pos |
|
| May 10, 2023 |
EX-FILING FEES 2 d465744dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form 424(b)(5) (Form Type) Beam Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maxim |
|
| May 10, 2023 |
Exhibit 1.1 AMENDMENT NO. 2 TO THE SALES AGREEMENT May 10, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 2 to the sales agreement (this “Amendment No. 2”) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties to that certain sal |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| May 10, 2023 |
Amended and Restated Beam Therapeutics Inc. Non-Employee Director Compensation Policy. Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of March 31, 2023) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the “Company”) as a director, other than a director who is employed by the Company or a subsidiary (a “Non-Employee Director”), shall be entitled to receive the following amounts of |
|
| May 10, 2023 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives Multiple Sites Activated and Additional Patients Enrolled in BEACON Clinical Trial of BEAM-101 for Patients with Sickle Cel |
|
| May 10, 2023 |
Up to $300,000,000 BEAM THERAPEUTICS INC. Common Stock 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254946 PROSPECTUS SUPPLEMENT (To Prospectus dated April 1, 2021) Up to $300,000,000 BEAM THERAPEUTICS INC. Common Stock We have entered into an amendment, dated May 10, 2023, or Amendment No. 2, to the Sales Agreement with Jefferies LLC, or the sales agent, dated April 1, 2021, or the sales agreement, as previously am |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 17, 2023 |
BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| February 28, 2023 |
FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (this “Fourth Amendment”) is made as of December 7, 2022 by and between MIT 238 MAIN STREET LEASEHOLD LLC, a Massachusetts charitable corporation with an address c/o MIT Cambridge Real Estate LLC, One Broadway, Suite 09-200, Cambridge, MA 02142 (“Landlord”), and BEAM THERAPEUTICS, INC. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. |
|
| February 28, 2023 |
Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines North Carolina Manufacturing Facility Open and Operatio |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 28, 2023 |
Second Amended and Restated Bylaws of Beam Therapeutics Inc. BEAM THERAPEUTICS INC. SECOND AMENDED AND RESTATED BYLAWS SECTION 1 — STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of Beam Therapeutics Inc., a Delaware corporation (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting shall be held at the place |
|
| February 28, 2023 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 par value per sha |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti |
|
| February 14, 2023 |
BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 13ga1beam.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 10, 2023 |
BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment SC 13G/A 1 d461102dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per |
|
| February 10, 2023 |
BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
BEAM / Beam Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Beam Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 9, 2023 |
EX-99.1 PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, progress and results of preclinical studies and research and development programs, |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BEAM THERAPEUTICS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 9, 2023 |
EX-99.2 Exhibit 99.2 Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL Expected by Mid-2023 Regulatory Submissions Planned for |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 7, 2022 |
Exhibit 99.1 Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Defi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 02, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| August 9, 2022 |
Exhibit 99.1 Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 on Track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022 John Lo, Ph.D., Appointed as Chief |
|
| August 1, 2022 |
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application EX-99.1 2 beam-ex991.htm EX-99.1 Exhibit 99.1 Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application CAMBRIDGE, Mass., August 1, 2022 – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, the company was informed via e-mail communication from the U.S. Food and D |
|
| August 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 14, 2022 |
BEAM / Beam Therapeutics Inc / Farallon Capital Partners, L.P. - INITIAL 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 9, 2022 |
Amended and Restated Non-employee Director Compensation Policy Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of March 31, 2022) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the ?Company?) as a director, other than a director who is employed by the Company or a subsidiary (a ?Non-Employee Director?), shall be entitled to receive the following amounts of |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| May 9, 2022 |
Exhibit 99.1 Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait to Provide Insights into Key Characteristics of Sickle Cell Trait and Sickle Ce |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| April 22, 2022 |
DEFA14A 1 beam2022proxymaterial.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| April 22, 2022 |
DEF 14A 1 beam2022noticeandpro.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| February 28, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Beam Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.01 pa |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 S-8 1 d313692ds8.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 81-5238376 (State or other jurisdiction of incorporatio |
|
| February 28, 2022 |
Exhibit 10.33 THIRD AMENDMENT TO LEASE This Third Amendment to Lease (this "Third Amendment") is made as of August 24th 2021 by and between MIT 238 MAIN STREET LEASEHOLD LLC, a Massachusetts charitable corporation with an address of c/o MIT Cambridge Real Estate LLC, One Broadway, Suite 09-200, Cambridge, MA 02142 ("Landlord"), successor-in-interest to Massachusetts Institute of Technology, and BE |
|
| February 28, 2022 |
Exhibit 10.32 SECOND AMENDMENT TO LEASE This Second Amendment to Lease (this ?Second Amendment?) is made as of November 17, 2020 by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a Massachusetts charitable corporation with an address of c/o MIT Investment Management Company, One Broadway, Suite 09-200, Cambridge, MA 02142 (?Landlord?), and BEAM THERAPEUTICS, INC., a Delaware corporation with a |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 28, 2022 |
Exhibit 99.1 Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of Long-term Strategy for Sickle Cell Disease with Planned Initiation of BEAM-101 Clinical Trial and IND Submiss |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti |
|
| February 28, 2022 |
Exhibit 10.31 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this ?First Amendment?) is made as of April 14th, 2020 by and between MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a Massachusetts charitable corporation with an address of c/o MIT Investment Management Company, One Broadway, Suite 09-200, Cambridge, MA 02142 Landlord?) and BEAM THERAPEUTICS, INC., a Delaware corporation with an addre |
|
| February 28, 2022 |
List of Subsidiaries of Beam Therapeutics Inc. Exhibit 21.1 Subsidiaries of Beam Therapeutics Inc. Entity State or other Jurisdiction of Incorporation or Organization Beam Therapeutics Securities Corporation Massachusetts Guide Therapeutics, LLC Delaware |
|
| February 28, 2022 |
Exhibit 10.27 Beam Therapeutics Inc. AMENDED AND RESTATED 2019 Employee Stock Purchase Plan 1. Defined Terms Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational rules related to those terms. 2. Purpose of Plan The Plan is intended to enable Eligible Employees to use payroll deductions to purchase shares of Stock in offerings under th |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Beam Therapeutics, Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the r |
|
| February 14, 2022 |
BEAM / Beam Therapeutics Inc / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Secur |
|
| February 14, 2022 |
BEAM / Beam Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) BEAM THERAPEUTICS Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.01 par value per share, of Beam Therapeutics Inc., |
|
| February 9, 2022 |
BEAM / Beam Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Beam Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 07373V105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ?? |
|
| February 9, 2022 |
BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2022 Beam Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2022 |
PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99. |
|
| January 10, 2022 |
Exhibit 99.2 Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022 BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Typ |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T |
|
| November 8, 2021 |
Exhibit 99.1 Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 8, 2021 -Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| August 10, 2021 |
Exhibit 99.1 Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 -Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company |
|
| August 10, 2021 |
Exhibit 10.2 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of June 10, 2021) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the ?Company?) as a director, other than a director who is employed by the Company or a subsidiary(a ?Non-Employee Director?), shall be entitled to receive the following |
|
| August 10, 2021 |
Exhibit 10.1 June 9, 2021 John Evans Dear John: This amended and restated letter agreement (this ?Agreement?) confirms the terms and conditions of your employment as the Chief Executive Officer of Beam Therapeutics Inc. (the ?Company?), working out of the Company?s headquarters located in Cambridge, Massachusetts, effective as of June 9, 2021 (the ?Effective Date?). 1. Position and Duties. a. Effe |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of i |
|
| July 7, 2021 |
Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254946 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0.01 par value per share $500,000,000.00 $54,550.00 (1) The securities registered herein are offered pursuant to an automatic shelf registration |
|
| July 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 7, 2021 |
Exhibit 1.1 AMENDMENT NO. 1 TO THE SALES AGREEMENT July 7, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this ?Amendment?) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the ?Company?), and Jefferies LLC (the ?Agent?), that are parties to that certain Sales Agr |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| June 10, 2021 |
BEAM / Beam Therapeutics Inc / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| June 10, 2021 |
As filed with the Securities and Exchange Commission on June 10, 2021 Table of Contents As filed with the Securities and Exchange Commission on June 10, 2021 Registration No. |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| May 11, 2021 |
Exhibit 99.1 Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 CAMBRIDGE, Mass., May 11, 2021 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnol |
|
| May 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| April 1, 2021 |
Exhibit 4.5 BEAM THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establish |
|
| April 1, 2021 |
Sales Agreement, dated April 1, 2021, by and between Beam Therapeutics Inc. and Jefferies LLC. Exhibit 1.1 BEAM THERAPEUTICS INC. SALES AGREEMENT April 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Beam Therapeutics Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s |
|
| April 1, 2021 |
424B7 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(3) Common Stock, $0. |
|
| April 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2021 Date of Report (Date of earliest event reported) BEAM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 1, 2021 |
424B7 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price (2) Amount of Registration Fee(3) Common Stock, $0. |
|
| April 1, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 1, 2021 Registration No. |
|
| April 1, 2021 |
424B5 Table of Contents CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, $0. |
|
| April 1, 2021 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes all material provisions of the common stock, par value $0.01 per share, of Beam Therapeutics Inc. The description of our common stock and certain provisions of our amended and restated certificate of incorporation, or our certificate of in |
|
| March 17, 2021 |
As filed with the Securities and Exchange Commission on March 17, 2021 Registration No. |
|
| March 15, 2021 |
Exhibit 99.1 Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team Bolstered by Appointment of Amy Simon, M.D., as Chief Medical Officer an |
|
| March 15, 2021 |
Form of Restricted Stock Award Agreement under the Beam Therapeutics Inc. 2019 Equity Incentive Plan Exhibit 10.26 Beam Therapeutics Inc. 2019 Equity Incentive Plan Restricted Stock Award Agreement This agreement (this ?Agreement?), is made effective as of [ ], 2020 (the ?Date of Grant?), by and between Beam Therapeutics Inc. (the ?Company?) and [] (the ?Participant?). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Beam Therapeutics Inc. 2019 |
|
| March 15, 2021 |
Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG BEAM THERAPEUTICS INC., GALILEO MERGER SUB I, INC., GALILEO MERGER SUB II, LLC, GUIDE THERAPEUTICS, INC., SHAREHOLDER REPRESENTATIVE SERVICES |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therapeuti |
|
| March 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of in |
|
| March 15, 2021 |
Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL. January 7, 2021 Office of Technology Development Harvard University Richard A. and Susan F. Smith Campus Center, Suite 727 1350 Massachusetts Avenue Cambridge, Massachusetts 02138 F |
|
| March 15, 2021 |
Exhibit 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL. First Amendment to License Agreement This First Amendment (?Amendment?), effective as of September 4, 2018, is entered into by and between Blink Therapeutics Inc., a corporation exis |
|
| March 15, 2021 |
List of Subsidiaries of Beam Therapeutics Inc. Exhibit 21.1 Subsidiaries of Beam Therapeutics, Inc. Entity State or other Jurisdiction of Incorporation or Organization Blink Therapeutics, Inc. Delaware Beam Therapeutics Securities Corporation Massachusetts Guide Therapeutics, LLC Delaware |
|
| March 15, 2021 |
Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO LICENSE AGREEMENT This Amendment (?Amendment No. 2?), effective as of March 27, 2020 (?Amendment No. 2 Effective Date?), is entered into by and between Beam Therap |
|
| March 15, 2021 |
Beam Therapeutics Inc. Non-Employee Director Compensation Policy, as amended Exhibit 10.29 Beam Therapeutics Inc. Non-Employee Director Compensation Policy (as amended and restated as of January 10, 2021) Effective as of the date set forth above, each individual who provides services to Beam Therapeutics Inc. (the ?Company?) as a director, other than a director who is employed by the Company or a subsidiary or a director who is affiliated with ARCH Venture Partners or F-Pr |
|
| March 15, 2021 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL. September 26, 2018 The Broad Institute, Office of Technology Inc. 415 Main Street Development Harvard University Cambridge, MA 02142 Richard A. and Susan F. Smith Campus Attn: Chief |
|
| March 15, 2021 |
Exhibit 10.25 Name: Number of Restricted Stock Units subject to Award: Date of Grant: Vesting Commencement Date: Beam Therapeutics Inc. 2019 Equity Incentive Plan Restricted Stock Unit Award Agreement This agreement (this ?Agreement?) evidences an award (this ?Award?) of restricted stock units granted by Beam Therapeutics Inc. (the ?Company?) to the individual named above (the ?Participant?), purs |
|
| March 15, 2021 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT BEAM THERAPEUTICS INC. TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO LICENSE AGREEMENT Harvard Case Nos: [**]; [**] This Amendment No. 1 to License Agreement (this ?Amendment No. 1?) is entered into as of December 12, 2017 (the ?Ame |
|
| February 23, 2021 |
Exhibit 99.1 Beam Therapeutics Announces Acquisition of Guide Therapeutics GuideTx?s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing CAMBRIDGE, Mass., Feb. 23, 2021 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced it |
|
| February 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BEAM THERAPEUTICS Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.01 par value per share, of Beam Therapeutics Inc., |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 5, 2021 |
SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Beam Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| February 5, 2021 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G, dated February 5, 2021 (the “Schedule 13G”), with respect to the common stock, par value $0.01 per share, of Beam Therapeutics Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Beam Therapeutics Inc. (Name of Issuer) Common Stock par value $0.01 per share (Title of Class of Securities) 07373V105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| January 19, 2021 |
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors EX-99.1 Exhibit 99.1 Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that it has agreed to sell 2,795,700 shares of its common stock to certain ins |
|
| January 19, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2021 Beam Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39208 81-5238376 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 19, 2021 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 16, 2021 (the “Effective Date”), among Beam Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company and the Purcha |
|
| January 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| January 12, 2021 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| January 12, 2021 |
PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99. |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2021 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of |
|
| November 10, 2020 |
Exhibit 99.1 Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99% On-target Editing and In Vivo Proof of Concept of Tumor Clearance Multiple Upcoming |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam T |
|
| October 1, 2020 |
Joint bookrunning managers J.P. Morgan Jefferies Barclays Lead manager Wedbush PacGrow 424B4 Table of Contents Pursuant to Rule 424(b)(4) Registration No. 333-249093 Prospectus 5,000,000 shares Beam Therapeutics Inc. Common stock We are offering 5,000,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “BEAM.” The last reported sale of our common stock on Nasdaq on September 25, 2020 was $26.76 per share. We are a |
|
| September 28, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on September 28, 2020 Registration No. |
|
| September 28, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 Beam Therapeutics Inc. [●] Shares of Common Stock Underwriting Agreement [●], 2020 J.P. Morgan Securities LLC Jefferies LLC Barclays Capital Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Barclays Capital In |
|
| September 28, 2020 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 September 28, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beam Therapeutics Inc. Registration Statement on Form S-1 |
|
| September 28, 2020 |
CORRESP BEAM THERAPEUTICS INC. 26 Landsdowne Street Cambridge, MA 02139 September 28, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Beam Therapeutics Inc. Registration Statement on Form S-1 (File No. 333-249093) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as ame |
|
| September 18, 2020 |
DRS Table of Contents Confidential Treatment Requested by Beam Therapeutics Inc. Pursuant to 17 CFR 200.83 As confidentially submitted to the Securities and Exchange Commission on September 18, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Beam Therapeutics Inc. (Exact name of regi |
|
| September 18, 2020 |
DRSLTR September 18, 2020 CONFIDENTIAL AND VIA EDGAR Draft Registration Statement Division of Corporation Finance U. |
|
| August 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Therap |
|
| August 12, 2020 |
Lease Agreement between Beam Therapeutics Inc. and ARE-NC Region No. 14, LLC Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this day of August, 2020, between ARE-NC REGION NO. 14, LLC, a Delaware limited liability company (“Landlord”), and BEAM THERAPEUTICS INC., a Delaware corporation (“Tenant”). Building: That certain to-be-constructed 1-story building with Mezzanine Space (as defined in Section 43(u)) to be known as 10 Davis Drive, Research Tri |
|
| August 12, 2020 |
Exhibit 99.1 Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to Producing Base Editing Therapeutics Broad Partnering Strategy Continues t |
|
| August 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of i |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39208 Beam Thera |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| May 12, 2020 |
Exhibit 99.1 Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo Novel HbG-Makassar Program for Sickle Cell Disease Demonstrates Direct Correction Levels Greater than 80% with |
|
| March 30, 2020 |
List of Subsidiaries of Beam Therapeutics Inc. Exhibit 21.1 Subsidiaries of Beam Therapeutics, Inc. Entity State or other Jurisdiction of Incorporation or Organization Blink Therapeutics, Inc. Delaware Beam Therapeutics Securities Corporation Massachusetts |
|
| March 30, 2020 |
Description of Registered Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following summary describes all material provisions of the common stock, par value $0.01 per share, of Beam Therapeutics Inc. The description of our common stock is qualified by reference to our certificate of incorporation, bylaws, and investor rights agreement, whic |
|
| March 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 BEAM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 001-39208 81-5238376 (State or other jurisdiction of incorporation) (Commissi |
